Vincent O'Neill's most recent trade in Iridium Communications Inc was a trade of 1,304 Common Stock done at an average price of $17.0 . Disclosure was reported to the exchange on Dec. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iridium Comm Inc | Vincent O’Neill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.04 per share. | 19 Dec 2025 | 1,304 | 47,463 (0%) | 0% | 17.0 | 22,220 | Common Stock |
| Iridium Comm Inc | Vincent O’Neill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.44 per share. | 01 Dec 2025 | 804 | 48,767 (0%) | 0% | 16.4 | 13,218 | Common Stock |
| Iridium Comm Inc | Vincent O’Neill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.89 per share. | 01 Sep 2025 | 804 | 49,571 (0%) | 0% | 24.9 | 20,012 | Common Stock |
| Iridium Comm Inc | Vincent O’Neill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.40 per share. | 01 Jun 2025 | 1,575 | 50,375 (0%) | 0% | 25.4 | 40,005 | Common Stock |
| Iridium Comm Inc | Vincent O’Neill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 23,764 | 50,749 (0%) | 0% | 0 | Common Stock | |
| Iridium Comm Inc | Vincent O’Neill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 2,187 | 52,936 (0%) | 0% | 0 | Common Stock | |
| Iridium Comm Inc | Vincent O’Neill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 01 Mar 2025 | 1,592 | 26,985 (0%) | 0% | 31.6 | 50,244 | Common Stock |
| Iridium Comm Inc | Vincent O’Neill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 01 Mar 2025 | 986 | 51,950 (0%) | 0% | 31.6 | 31,118 | Common Stock |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Dec 2024 | 521 | 20,122 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Dec 2024 | 521 | 2,606 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Dec 2024 | 165 | 19,957 (0%) | 0% | 0.4 | 58 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 17 Sep 2024 | 21,250 | 25,157 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 17 Sep 2024 | 5,556 | 19,601 (0%) | 0% | 0.6 | 3,056 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Sep 2024 | 521 | 4,045 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Sep 2024 | 521 | 3,127 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Sep 2024 | 138 | 3,907 (0%) | 0% | 0.7 | 95 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 1,875 | 1,875 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Jun 2024 | 521 | 3,648 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Jun 2024 | 521 | 3,679 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Jun 2024 | 155 | 3,524 (0%) | 0% | 1.3 | 199 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 2,250 | 6,750 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 2,250 | 5,573 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 521 | 4,169 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 521 | 3,323 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 165 | 5,408 (0%) | 0% | 2.6 | 432 | Common Stock | |
| BioXcel Therapeutics Inc | J. Vincent O'Neill | Chief Medical Officer | 14 Dec 2023 | 521 | 4,690 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | J. O'Neill Vincent | Chief Medical Officer | 14 Dec 2023 | 521 | 2,802 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 14 Sep 2023 | 521 | 5,211 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 14 Sep 2023 | 521 | 2,281 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 14 Jun 2023 | 521 | 1,760 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 14 Jun 2023 | 521 | 5,732 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 6,253 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 2,084 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 14 Mar 2023 | 845 | 1,239 (0%) | 0% | 19.7 | 16,642 | Common Stock |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 20 Jan 2023 | 29,713 | 29,712 | - | - | Employee Stock Option (right to buy) | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 20 Jan 2023 | 29,713 | 0 (0%) | 0% | 30 | 891,390 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 20 Jan 2023 | 29,713 | 29,713 (0%) | 0% | 0.4 | 12,182 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 14 Mar 2022 | 8,337 | 8,337 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 25 Mar 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) |